You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
12 January 2026 - Biopharmaceutical company Viking Therapeutics Inc (NASDAQ: VKTX) on Monday announced publication of results from its Phase 2 VENTURE trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the peer-reviewed journal Obesity. D...
12 January 2026 - Oncology company AbbVie (NYSE: ABBV) and biopharmaceutical company RemeGen announced on Monday that the companies have entered into an exclusive licensing agreement for the development, manufacturing and commercialisation of RC148, ...
12 January 2026 - Medical technology company Boston Scientific Corporation (NYSE: BSX) announced on Monday that it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focus...
12 January 2026 - Taiwanese biotechnology company Formosa Pharmaceuticals, Inc. (TWSE: 6838) announced on Monday that it has entered an exclusive licensing agreement with South Korea-based pharmaceutical manufacturer Samil Pharmaceuticals Co., Ltd. (...
12 January 2026 - Biotechnology company NewcelX Ltd (Nasdaq: NCEL) on Monday reported positive results from an international collaborative study evaluating advanced biomaterial strategies to support delivery and function of stem cell-derived islets f...
12 January 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Monday that it has entered into a clinical trial collaboration with biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) to evaluate ivonescimab...
12 January 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Monday that it has submitted a Biologics License Application to the US Food and Drug Administration (FDA) seeking approval for ivonescimab in comb...